FULC FULCRUM THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, FULCRUM THERAPEUTICS INC reported revenue of n/a, net income of −$26.2M and diluted EPS of −$0.34; for the fiscal year ended December 2025 revenue was $0, down 100.0% on the year before.
FULC annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$84.8M, net income −$74.9M (margin n/a), EPS −$1.18
- Fiscal year ended Dec 2024: revenue $80.0M, gross profit n/a, operating income −$21.9M, net income −$9.73M (margin -12.2%), EPS −$0.16
- Fiscal year ended Dec 2023: revenue $2.81M, gross profit n/a, operating income −$111M, net income −$97.3M (margin -3470.2%), EPS −$1.59
- Fiscal year ended Dec 2022: revenue $6.34M, gross profit n/a, operating income −$113M, net income −$110M (margin -1732.4%), EPS −$2.44
- Fiscal year ended Dec 2021: revenue $19.2M, gross profit n/a, operating income −$81.1M, net income −$80.8M (margin -421.9%), EPS −$2.29
FULC quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$26.2M, EPS −$0.34
- Quarter ended Mar 31, 2026: revenue n/a, net income −$18.9M, EPS −$0.25
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$20.3M, EPS −$0.31
- Quarter ended Sep 30, 2025: revenue $0, net income −$19.6M, EPS −$0.31
- Quarter ended Jun 30, 2025: revenue $0 (down 100.0% year over year), net income −$17.3M, EPS −$0.28
- Quarter ended Mar 31, 2025: revenue n/a, net income −$17.7M, EPS −$0.28
- Quarter ended Dec 31, 2024 (from the annual report): revenue $0 (down 100.0% year over year), net income −$16.6M, EPS −$0.25
- Quarter ended Sep 30, 2024: revenue $0 (down 100.0% year over year), net income −$21.7M, EPS −$0.35
- Quarter ended Jun 30, 2024: revenue $80.0M (up 8990.9% year over year), net income $55.4M, EPS $0.87
- Quarter ended Mar 31, 2024: revenue $0 (down 100.0% year over year), net income −$26.9M, EPS −$0.43
- Quarter ended Dec 31, 2023 (from the annual report): revenue $871K (up 27.2% year over year), net income −$24.8M, EPS −$0.41
- Quarter ended Sep 30, 2023: revenue $759K (down 35.8% year over year), net income −$24.0M, EPS −$0.39
- Quarter ended Jun 30, 2023: revenue $880K (down 53.2% year over year), net income −$23.8M, EPS −$0.38
- Quarter ended Mar 31, 2023: revenue $295K (down 88.6% year over year), net income −$24.8M, EPS −$0.41
- Quarter ended Dec 31, 2022 (from the annual report): revenue $685K (down 86.5% year over year), net income −$26.1M, EPS −$0.46
- Quarter ended Sep 30, 2022: revenue $1.18M (down 76.0% year over year), net income −$23.7M, EPS −$0.51
- Quarter ended Jun 30, 2022: revenue $1.88M (down 57.0% year over year), net income −$34.1M, EPS −$0.83
- Quarter ended Mar 31, 2022: revenue $2.59M (down 45.9% year over year), net income −$25.9M, EPS −$0.64
- Quarter ended Dec 31, 2021 (from the annual report): revenue $5.06M, net income −$23.5M, EPS −$0.58
- Quarter ended Sep 30, 2021: revenue $4.94M, net income −$20.7M, EPS −$0.57
FULC cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$60.1M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$2.22M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$91.0M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$97.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$78.5M, share buybacks n/a
FULC balance sheet
- Jun 30, 2026: cash $48.5M, total assets $324M, total liabilities $13.3M, shareholders' equity $311M
- Mar 31, 2026: cash $50.3M, total assets $347M, total liabilities $13.5M, shareholders' equity $333M
- Dec 31, 2025: cash $198M, total assets $366M, total liabilities $17.3M, shareholders' equity $349M
- Sep 30, 2025: cash $47.1M, total assets $215M, total liabilities $16.5M, shareholders' equity $198M
- Jun 30, 2025: cash $42.6M, total assets $229M, total liabilities $14.5M, shareholders' equity $214M
- Mar 31, 2025: cash $42.2M, total assets $243M, total liabilities $14.2M, shareholders' equity $228M
- Dec 31, 2024: cash $58.2M, total assets $261M, total liabilities $17.7M, shareholders' equity $243M
- Sep 30, 2024: cash $72.6M, total assets $279M, total liabilities $21.7M, shareholders' equity $257M
What is FULC's revenue?
FULCRUM THERAPEUTICS INC reported $0 of revenue for the fiscal year ended December 2025.
Is FULC profitable?
No. FULCRUM THERAPEUTICS INC lost $85.0M over the last four quarters.
What is FULC's EPS?
Diluted earnings per share over the last four quarters were −$1.21; −$0.34 in the latest quarter.